Media stories about Neogen (NASDAQ:NEOG) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neogen earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.7386489445311 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Neogen (NASDAQ NEOG) traded up $0.16 during midday trading on Wednesday, reaching $63.82. The company had a trading volume of 171,339 shares, compared to its average volume of 175,505. The firm has a market capitalization of $3,260.35, a P/E ratio of 63.34, a price-to-earnings-growth ratio of 3.92 and a beta of 1.42. Neogen has a 1-year low of $44.63 and a 1-year high of $64.44.
Neogen (NASDAQ:NEOG) last posted its quarterly earnings data on Wednesday, January 3rd. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.07. The business had revenue of $101.80 million during the quarter, compared to the consensus estimate of $102.46 million. Neogen had a return on equity of 10.72% and a net margin of 13.47%. Neogen’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 earnings per share. research analysts forecast that Neogen will post 1.08 EPS for the current year.
NEOG has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Neogen from a “hold” rating to a “buy” rating and set a $69.75 price target for the company in a report on Wednesday, November 29th. Roth Capital initiated coverage on shares of Neogen in a report on Tuesday, December 5th. They set a “neutral” rating and a $61.50 price target for the company. Craig Hallum upped their price target on shares of Neogen from $46.50 to $60.00 and gave the stock a “hold” rating in a report on Thursday, December 7th. BidaskClub upgraded Neogen from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, Stephens restated a “hold” rating and issued a $62.00 price objective on shares of Neogen in a report on Wednesday, January 10th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $63.25.
In other Neogen news, VP Edward Bradley sold 11,725 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $60.29, for a total transaction of $706,900.25. Following the sale, the vice president now owns 21,412 shares of the company’s stock, valued at $1,290,929.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James L. Herbert sold 25,334 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $59.32, for a total transaction of $1,502,812.88. Following the sale, the insider now directly owns 1,157,591 shares in the company, valued at approximately $68,668,298.12. The disclosure for this sale can be found here. Insiders sold 66,382 shares of company stock valued at $3,939,913 over the last 90 days. 4.20% of the stock is currently owned by company insiders.
Neogen Company Profile
Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation.
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.